Ann: IND clearance received from US FDA for CHM 1101, page-24

We need to move forward just one step at a time.

Lets get this phase 1 done. It has been running for almost a year, so with covid delays, it has another 6 to 9 months to run (hopefully more information on that in the update due next quarter.)
After that, the company has already stated it will accelerate into a phase 2b trial, which hopefully will be enough for FDA drug approval. This is huge for a cancer treatment with no approved competition. If its safety is as good as they have suggested in the prospectus and pervious announcements, the available patient cohort will be huge. This means a market cap many multiples of where we are today before it even hits the treatment clinic. This is why CHM may be able to go it alone, as a phase 3 trial will not be required. Huge cost and time saving right there.

Take a look at the early presentations and prospectus, they do talk about the drug manufacturing, and it was picked because it presented no problems.

And then comes revenue.

And then comes expansion into different cancer treatments, and development of new drugs. Targeting an aggressive cancer with no SOC, means there is an unmet need. The unmet need bit is why CLTX will be a candidate for fast track approval, if supported by good data.

For a biotech company that only publicly list 7 months ago, CHM is well down the development highway. There is a lot of bang for the $aud100 million market cap.